First Time Loading...

Neogenomics Inc
NASDAQ:NEO

Watchlist Manager
Neogenomics Inc Logo
Neogenomics Inc
NASDAQ:NEO
Watchlist
Price: 14.03 USD -0.92% Market Closed
Updated: Apr 25, 2024

Intrinsic Value

NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. [ Read More ]

The intrinsic value of one NEO stock under the Base Case scenario is 12.21 USD. Compared to the current market price of 14.03 USD, Neogenomics Inc is Overvalued by 13%.

Key Points:
NEO Intrinsic Value
Base Case
12.21 USD
Overvaluation 13%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Neogenomics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling NEO stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Neogenomics Inc

Provide an overview of the primary business activities
of Neogenomics Inc.

What unique competitive advantages
does Neogenomics Inc hold over its rivals?

What risks and challenges
does Neogenomics Inc face in the near future?

Has there been any significant insider trading activity
in Neogenomics Inc recently?

Summarize the latest earnings call
of Neogenomics Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Neogenomics Inc.

Provide P/S
for Neogenomics Inc.

Provide P/E
for Neogenomics Inc.

Provide P/OCF
for Neogenomics Inc.

Provide P/FCFE
for Neogenomics Inc.

Provide P/B
for Neogenomics Inc.

Provide EV/S
for Neogenomics Inc.

Provide EV/GP
for Neogenomics Inc.

Provide EV/EBITDA
for Neogenomics Inc.

Provide EV/EBIT
for Neogenomics Inc.

Provide EV/OCF
for Neogenomics Inc.

Provide EV/FCFF
for Neogenomics Inc.

Provide EV/IC
for Neogenomics Inc.

Show me price targets
for Neogenomics Inc made by professional analysts.

What are the Revenue projections
for Neogenomics Inc?

How accurate were the past Revenue estimates
for Neogenomics Inc?

What are the Net Income projections
for Neogenomics Inc?

How accurate were the past Net Income estimates
for Neogenomics Inc?

What are the EPS projections
for Neogenomics Inc?

How accurate were the past EPS estimates
for Neogenomics Inc?

What are the EBIT projections
for Neogenomics Inc?

How accurate were the past EBIT estimates
for Neogenomics Inc?

Compare the revenue forecasts
for Neogenomics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Neogenomics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Neogenomics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Neogenomics Inc compared to its peers.

Compare the P/E ratios
of Neogenomics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Neogenomics Inc with its peers.

Analyze the financial leverage
of Neogenomics Inc compared to its main competitors.

Show all profitability ratios
for Neogenomics Inc.

Provide ROE
for Neogenomics Inc.

Provide ROA
for Neogenomics Inc.

Provide ROIC
for Neogenomics Inc.

Provide ROCE
for Neogenomics Inc.

Provide Gross Margin
for Neogenomics Inc.

Provide Operating Margin
for Neogenomics Inc.

Provide Net Margin
for Neogenomics Inc.

Provide FCF Margin
for Neogenomics Inc.

Show all solvency ratios
for Neogenomics Inc.

Provide D/E Ratio
for Neogenomics Inc.

Provide D/A Ratio
for Neogenomics Inc.

Provide Interest Coverage Ratio
for Neogenomics Inc.

Provide Altman Z-Score Ratio
for Neogenomics Inc.

Provide Quick Ratio
for Neogenomics Inc.

Provide Current Ratio
for Neogenomics Inc.

Provide Cash Ratio
for Neogenomics Inc.

What is the historical Revenue growth
over the last 5 years for Neogenomics Inc?

What is the historical Net Income growth
over the last 5 years for Neogenomics Inc?

What is the current Free Cash Flow
of Neogenomics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Neogenomics Inc.

Financials

Balance Sheet Decomposition
Neogenomics Inc

Current Assets 596.8m
Cash & Short-Term Investments 415.2m
Receivables 131.3m
Other Current Assets 50.3m
Non-Current Assets 1.1B
PP&E 183.8m
Intangibles 895.9m
Other Non-Current Assets 4.7m
Current Liabilities 96.3m
Accounts Payable 20.3m
Accrued Liabilities 73.8m
Other Current Liabilities 2.1m
Non-Current Liabilities 643.4m
Long-Term Debt 538.2m
Other Non-Current Liabilities 105.2m
Efficiency

Earnings Waterfall
Neogenomics Inc

Revenue
591.6m USD
Cost of Revenue
-347m USD
Gross Profit
244.6m USD
Operating Expenses
-341.3m USD
Operating Income
-96.6m USD
Other Expenses
8.7m USD
Net Income
-88m USD

Free Cash Flow Analysis
Neogenomics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

NEO Profitability Score
Profitability Due Diligence

Neogenomics Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive 3-Years Revenue Growth
Positive Revenue Growth Forecast
Positive 1-Year Revenue Growth
31/100
Profitability
Score

Neogenomics Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.

NEO Solvency Score
Solvency Due Diligence

Neogenomics Inc's solvency score is 49/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Long-Term Solvency
Positive Net Debt
49/100
Solvency
Score

Neogenomics Inc's solvency score is 49/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

NEO Price Targets Summary
Neogenomics Inc

Wall Street analysts forecast NEO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NEO is 21.98 USD with a low forecast of 18.18 USD and a high forecast of 31.5 USD.

Lowest
Price Target
18.18 USD
30% Upside
Average
Price Target
21.98 USD
57% Upside
Highest
Price Target
31.5 USD
125% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

NEO Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

NEO Price
Neogenomics Inc

1M 1M
-5%
6M 6M
-4%
1Y 1Y
-2%
3Y 3Y
-73%
5Y 5Y
-31%
10Y 10Y
+319%
Annual Price Range
14.03
52w Low
11.67
52w High
20.73
Price Metrics
Average Annual Return 5.51%
Standard Deviation of Annual Returns 73.84%
Max Drawdown -89%
Shares Statistics
Market Capitalization 1.8B USD
Shares Outstanding 127 610 000
Percentage of Shares Shorted 7.88%

NEO Return Decomposition
Main factors of price return

What is price return decomposition?

NEO News

Other Videos

Company Profile

Neogenomics Inc Logo
Neogenomics Inc

Country

United States of America

Industry

Life Sciences Tools & Services

Market Cap

1.8B USD

Dividend Yield

0%

Description

NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. The company is headquartered in Fort Myers, Florida and currently employs 2,000 full-time employees. The company went IPO on 2012-12-10. The firm operates through two segments: the Clinical Services Segment and the Pharma Services Segment. The Clinical Services segment provides various clinical testing services to community-based pathology practices, oncology practices, hospital pathology labs, reference labs, and academic centers with reimbursement from various payers, including client direct billing, commercial insurance, Medicare and other government payers, and patients. The Pharma Services segment supports pharmaceutical firms in their drug development programs by providing testing services and data analytics for clinical trials and research. The company offers testing services, which include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry (IHC) and digital imaging, molecular testing and morphologic analysis. The company operates testing laboratories in United States, Europe and Asia.

Contact

FLORIDA
Fort Myers
9490 Neogenomics Way
+12397680600.0
https://neogenomics.com/

IPO

2012-12-10

Employees

2 000

Officers

CEO & Director
Mr. Christopher Michael Smith BSc
Chief Financial Officer
Mr. Jeffrey S. Sherman M.B.A.
President of Clinical Division
Mr. Warren Stone
President of Pharma Services, President & Chief Commercial Officer Inivata
Mr. Vishal Sikri
Senior VP & Chief Accounting Officer
Gregory D. Aunan
Vice President of Investor Relations & Communications
Ms. Kendra Sweeney
Show More
General Counsel & Corporate Secretary
Ms. Alicia Olivo
Chief Compliance Officer
Mr. Hutan Hashemi J.D.
Chief Medical Officer
Dr. Derek Lyle M.D.
President of Enterprise Operations
Ms. Melody Harris Esq., J.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one NEO stock?

The intrinsic value of one NEO stock under the Base Case scenario is 12.21 USD.

Is NEO stock undervalued or overvalued?

Compared to the current market price of 14.03 USD, Neogenomics Inc is Overvalued by 13%.